ZYBT

Zhengye Biotechnology Holding Limited

There isn't enough reported data to score ZYBT yet.

ZYBT Fundamentals

MetricStatus
Unavailable
Weak
Unavailable
Healthy

ZYBT's balance sheet is currently healthy, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.

ZYBT PE Valuation

ZYBT has no meaningful PE right now: it lost money over the past year.

ZYBT Forward outlook

There aren't enough analyst estimates for ZYBT to show an outlook.

ZYBT Risk to reward

ScenarioChangePrice
UpsideUnknown—
DownsideUnknown—

Calculated from the latest close: $1.50 on Nov 12.

There is not enough scenario data to assess ZYBT's risk to reward.

ZYBT Earnings Per Share

Q4 2024: $0.04Q4 2025: $-0.22Q2 2026: $-0.21
Q4 2024: $0.04Q4 2025: $-0.22Q2 2026: $-0.21
QuarterTTM EPSYoY
Q4 2025-$0.22-650%

ZYBT Quarterly Revenue

Q1 2022: --Q2 2022: --Q3 2022: --Q4 2022: --Q1 2023: --Q2 2023: --Q3 2023: --Q4 2023: --Q4 2024: $28MQ2 2025: $9MQ4 2025: $8MQ2 2026: $8M
Q1 2022: --Q2 2022: --Q3 2022: --Q4 2022: --Q1 2023: --Q2 2023: --Q3 2023: --Q4 2023: --Q4 2024: $28MQ2 2025: $9MQ4 2025: $8MQ2 2026: $8M
QuarterRevenueYoY
Q2 2026$7.6M-18%
Q4 2025$8.1M-71%

ZYBT Free Cash Flow

Q1 2022: −$852,255Q2 2022: −$2MQ3 2022: $102,424Q4 2022: $343,050Q1 2023: $511,593Q2 2023: $511,593Q3 2023: $3MQ4 2023: $3MQ4 2024: $4MQ2 2025: −$2MQ4 2025: $4MQ2 2026: −$3M
Q1 2022: −$852,255Q2 2022: −$2MQ3 2022: $102,424Q4 2022: $343,050Q1 2023: $511,593Q2 2023: $511,593Q3 2023: $3MQ4 2023: $3MQ4 2024: $4MQ2 2025: −$2MQ4 2025: $4MQ2 2026: −$3M
QuarterFree cash flowYoY
Q2 2026-$3M-$895.5K
Q4 2025$4M-3.3%
Q4 2024$4.1M+62%
Q4 2023$2.5M+643%
Q3 2023$2.5M+2389%
Q2 2023$511.6K+$2.3M
Q1 2023$511.6K+$1.4M

ZYBT usually generates cash, though not every quarter: the latest was −$3M, but it generated $3M over the past year.

ZYBT Total Shares

Q4 2024: 46MQ2 2025: 47MQ4 2025: 47MQ2 2026: 47M
Q4 2024: 46MQ2 2025: 47MQ4 2025: 47MQ2 2026: 47M
PeriodChange %Net change
Quarterly+0.1%+41.5K shares

ZYBT Net Leverage

Q4 2024: 1.7x
Q4 2024: 1.7x
QuarterNet LeverageStatus
Q4 20241.7xHealthy

ZYBT's net debt is about 1.7 years of its operating earnings (EBITDA).

ZYBT Weekly Momentum

MetricValueStatus
RSI51.4Neutral
Stochastic14.1Oversold

ZYBT's weekly RSI is 51 (neutral) and its Stochastic is 14 (oversold).

ZYBT PE vs Healthcare Sector

MetricZYBTSector medianRelative
PEN/A26x—

ZYBT has no meaningful PE right now: it lost money over the past year.

ZYBT Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$1.444.2% above
20 week MA$1.425.6% above
50 week MA$1.1926% above

ZYBT is in an uptrend: it's above all three of its weekly moving averages, and 26% above its 50-week average.

ZYBT Yearly ROI

YearStart priceEnd priceROI
2025$4.62$1.53-67%
2026 YTD$1.53$1.50-2%

ZYBT has finished every year since 2025 lower, and it's down 2% so far in 2026.

Give your agent the market.

Get API key